Picture of Filana Therapeutics logo

FLNA Filana Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Brief: Cassava Sciences Announces Completion Of An Interim Safety Review Of Oral Simufilam On-Going Phase 3 Trials

Sept 24 (Reuters) - Cassava Sciences Inc  SAVA.O :
    * CASSAVA SCIENCES ANNOUNCES COMPLETION OF AN INTERIM SAFETY
REVIEW OF ORAL SIMUFILAM ON-GOING PHASE 3 TRIALS
    * CASSAVA SCIENCES INC - DSMB RECOMMENDS CONTINUATION OF
PHASE 3
TRIALS WITHOUT MODIFICATION
    * CASSAVA SCIENCES INC - FINAL SAFETY DATA FOR SIMUFILAM
EXPECTED
AT PHASE 3 CONCLUSION

Source text for Eikon:  ID:nGNX4pK6xp 
Further company coverage:  SAVA.O 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Filana Therapeutics

See all news